Onesource Specialty Pharma Ltd. announced on Saturday, May 16, that it has received in-principle approval from the Government of Karnataka for the Unit II expansion project under the Karnataka Industrial Policy (KIP) 2025-30. According to the company's disclosure under Regulation 30 to BSE and NSE on May 16, 2026, the Government Order bearing No. CI 120 SPI 2026 was received on May 15, 2026, following the 67th State High Level Clearance Committee meeting held on April 13, 2026. The approval covers incentives and concessions associated with the company's proposed investment in expanding its manufacturing infrastructure at Unit II, which is described as a flagship facility of the company. This development is primarily aimed at increasing manufacturing capabilities to better serve its global partners, with the expansion designed to boost the company's production capacity for its international clients under the state's industrial policy framework.
The company reported its fourth quarter earnings this week, showing mixed financial results. As reported by CNBC TV18, its consolidated net profit declined to ₹4.6 crore from ₹98.5 crore in the previous year, while revenue increased marginally to ₹428.2 crore from ₹426 crore in the previous year. The company's EBITDA declined 50% to ₹92 crore from ₹182 crore, and its EBITDA margin contracted to 21.5% from 42.7% in the year-ago period.
Despite the financial challenges, Onesource Specialty Pharma shares showed positive momentum in recent trading. According to CNBC TV18, shares ended the previous trading session 0.7% up at ₹1,833 apiece. The stock has demonstrated strong performance with a 21.7% gain in the past month, indicating investor confidence in the company's expansion plans and long-term growth prospects. Historical stock returns show the stock has gained 18.75% in one day and 14.73% over the past month.
